Found 27 articles
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy — After Two Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels— — Majority of Patients Treated Daily Also Reported Lower Rates of Adverse Events and Showed Higher Rates of Desensitization Compared to Non-Daily Dosing Groups —
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
Aimmune Therapeutics, Inc. today announced that the first patients in the United States are being treated with PALFORZIA™ [Peanut ( Arachis hypogaea ) Allergen Powder-dnfp], the first approved treatment for peanut allergy. Following the release of the medication lots by the U.S. Food an
DBV announced positive topline results from its Phase III PEPITES trial evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children aged 4 to 11 years.
FARE said the biomarker research project, which will be conducted at Janssen’s World Without Disease Accelerator, “has the potential to make a real and significant impact for the 32 million Americans living with food allergies.”
AR101 is an investigational, peanut-derived, biologic drug candidate for oral immunotherapy in patients with peanut allergy. It delivers a daily dose of peanut protein with a consistent protein profile.
Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will present new data on the safety and efficacy of the company’s lead investigational candidate, AR101 (trade name Palforzia™), at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place November 7-11, 2019, in Houston
Aimmune’s peanut allergy treatment is one-step closer to approval following strong support from the Allergenic Products Advisory Committee, which overwhelmingly recommended approval of Palforzia, the proposed trade name of the investigational oral treatment, AR101.